A pharmaceutical giant valued at roughly $1.135 trillion, Eli Lilly (NYSE: LLY) heads into its October 29 third-quarter earnings report with an uncomfortably concentrated revenue base.
Two drugs, Mounjaro and Zepbound, generated a combined $14.9 billion last quarter alone, making tirzepatide the engine powering nearly everything investors have priced into the stock.
Shares have climbed 19.07% year to date and added another 10.64% in just the past month, meaning expectations entering Wednesday’s report are already elevated.
Lilly arrives at the print carrying a five-quarter streak of consecutive earnings-per-share beats, a record that has conditioned the market to expect outperformance.
Yet Q3 EPS estimates have collapsed from $9.8749 a month ago to a consensus of $6.6684, driven by seven downward revisions against only three upward, as acquired in-process research and development charges from recent deal activity weigh on non-GAAP figures.
On the revenue side, Wall Street is projecting $22.62 billion for the quarter, a 28.5% year-over-year gain, while the full-year consensus of $88.68 billion already exceeds the top of management’s own raised guidance range of $85 billion to $87 billion.
That gap between the Street’s expectations and the company’s stated range sets up the first major catalyst: whether Lilly will raise full-year guidance for a third consecutive time.
International tirzepatide momentum is the variable to watch, given that Mounjaro posted 172% international growth in Q2 following its inclusion in China’s National Reimbursement Drug List.
Domestically, U.S. pricing remains a pressure point after falling 9% last quarter excluding rebate adjustments, though CFO Lucas Montarce pushed back on that concern, saying, “We’re going to more than offset that with volume growth.”
Expansion of the Medicare GLP-1 Bridge program, which broadened access to Lilly’s obesity treatments by 35%, is expected to show up in Zepbound volume figures and will be closely scrutinized.
Beyond tirzepatide, investors will be focused on Foundayo, which generated $98 million in its launch quarter and was described by management as “almost doubling” in volume by late July compared to the prior month.
The longer-term diversification story hinges on retatrutide, for which Lilly is targeting a U.S. biologics license application submission in the first quarter of 2027.
CEO David Ricks stated the company has “all the clinical data we need to submit,” with manufacturing work described as the remaining hurdle before regulators can review the drug.
Competitive pressure from Novo Nordisk (NYSE: NVO) adds another layer of uncertainty, even as Lilly claims Zepbound delivered superior weight loss compared to Novo’s Wegovy HD in an indirect study comparison.
History also warns that beating consensus is no guarantee of a positive stock reaction, as Lilly surpassed EPS estimates in Q2 2025 and still saw its shares drop 14.14% on the day of that report.
